Hisako Fujii

Dr. Hisako Fujii

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Atherosclerosis
Verified
Journal Article
Closed access
Hidenori KoyamaHidenori Koyama
Hidenori Koyama
STShinji Tanaka
Shinji Tanaka
MMMasayo Monden
Masayo Monden
TSTakuhito Shoji
Takuhito Shoji
TMTomoaki Morioka
Tomoaki Morioka
MIMasaaki Inaba
Masaaki Inaba

27 September 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
SNShinya Nakatani
Shinya Nakatani
TSTetsuo Shoji
Tetsuo Shoji
FMFumiyuki Morioka
Fumiyuki Morioka
RNRino Nakaya
Rino Nakaya
MUMayuko Ueda
Mayuko Ueda
MEMasanori Emoto
Masanori Emoto
Background/Objectives: Zinc is an essential microelement, and its deficiency is common in patients undergoing hemodialysis. However, the association between serum zinc and mortality in these patients remains unclear. The aim of this study was to explore the possible association between serum zinc levels and all-cause mortality in prevalent patients with kidney failure on maintenance hemodialysis. Methods: This was a prospective cohort study of maintenance hemodialysis patients followed up for 5 years. The key exposure was serum zinc level measured at baseline, and the outcome was all-cause mortality. Their association was analyzed using Cox proportional hazard models. Results: Among 1662 eligible patients selected for this analysis, 468 (28%) died. Lower serum zinc levels were associated with a higher risk for mortality, independent of the major demographic factors and factors including mineral and bone disorder and renal anemia. However, this association was no longer significant when adjusted for serum albumin. Because there was a close correlation between serum zinc and albumin levels, we performed further analyses in which participants were categorized into four groups by median serum zinc (68 µg/dL) and albumin (3.7 g/dL) levels. In the lower serum albumin groups, risk of death was significantly higher in those with lower zinc than those with higher zinc levels, whereas such a difference was not significant in the high serum albumin groups. Conclusions: In patients undergoing maintenance hemodialysis with lower serum albumin levels, a lower serum zinc level was associated with a higher risk of mortality.

3 November 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
TSTetsuo Shoji
Tetsuo Shoji
MKMori Katsuhito
Mori Katsuhito
YNYu Nagakura
Yu Nagakura
DKDaijiro Kabata
Daijiro Kabata
KKKaori Kuriu
Kaori Kuriu
MEMasanori Emoto
Masanori Emoto
Cognitive impairment and dementia are common in patients with chronic kidney disease, including those undergoing hemodialysis. Since magnesium and phosphate play important roles in brain function and aging, alterations in these and other factors related to bone mineral disorder (MBD) may contribute to low cognitive performance in patients on hemodialysis. This cross-sectional study examined the associations between cognitive function and MBD-related factors among 1207 patients on maintenance hemodialysis. Cognitive function was assessed by the Modified Mini-Mental State examination (3MS). The exposure variables of interest were serum magnesium, phosphate, calcium, calcium–phosphate product, intact parathyroid hormone, fetuin-A, T50 calciprotein crystallization test, use of phosphate binders, use of cinacalcet, and use of vitamin D receptor activators. Multivariable-adjusted linear regression models were used to examine the associations between 3MS and each of the exposure variables independent of 13 potential non-mineral confounders. We found that lower 3MS was associated with lower serum magnesium, lower phosphate, lower calcium–phosphate product, and nonuse of phosphate binders. These results suggest that magnesium and phosphate play potentially protective roles against cognitive impairment in this population.

1 September 2013 in Journal of Renal Nutrition
Verified
Journal Article
Closed access
PDF file
HFHisako Fujii
Hisako Fujii
Hidenori KoyamaHidenori Koyama
Hidenori Koyama
SFSanae Fukuda
Sanae Fukuda
HTHidekichi Tokai
Hidekichi Tokai
STSeiki Tajima
Seiki Tajima
YNYoshiki Nishizawa
Yoshiki Nishizawa

1 December 2017 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
HKHiroyuki Kusuhara
Hiroyuki Kusuhara
TTTadayuki Takashima
Tadayuki Takashima
HFHisako Fujii
Hisako Fujii
TTTsutomu Takashima
Tsutomu Takashima
MTMasaaki Tanaka
Masaaki Tanaka
Yasuyoshi WatanabeYasuyoshi Watanabe
Yasuyoshi Watanabe

18 April 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YMYuichiro Miki
Yuichiro Miki
SNSatoshi Nishi
Satoshi Nishi
TTTatsuro Tamura
Tatsuro Tamura
TITakumi Imai
Takumi Imai
MNMikio Nambara
Mikio Nambara
KMKiyoshi Maeda
Kiyoshi Maeda
Background: Subtotal esophagectomy with lymph node dissection followed by neoadjuvant chemotherapy (NAC) is the standard treatment for stage II–III esophageal cancer. Esophagectomy is still associated with high morbidity rates, and reducing these rates remains challenging. Among several complications, postoperative pneumonia (PP) is sometimes fatal, which has been reportedly caused by sarcopenia. Thus, nutritional support and rehabilitation may be promising for preventing skeletal muscle mass loss and reduce the incidence of PP. Methods: This single-center, randomized, open-label, pilot trial will randomize a total of 40 patients with esophageal cancer in a 1:1 ratio either to ISOCAL Clear + rehabilitation arm or only rehabilitation arm. Although all patients will be educated about rehabilitation by a specialized physician and will be asked to undergo the prespecified rehabilitation program, patients treated with ISOCAL Clear + rehabilitation arm will be supplemented by 400 mL of ISOCAL Clear (Nestlé Japan Ltd, Tokyo, Japan) per day during two courses of NAC with docetaxel, cisplatin, and fluorouracil. Body composition will be assessed using Inbody (Inbody Co., Ltd., Tokyo, Japan) just before starting NAC and surgery. The primary endpoint is the change of skeletal muscle index (SMI) during NAC. Secondary endpoints include (i) body weight, total skeletal muscle mass, appendicular skeletal muscle mass, and lean body mass index changes; (ii) the percentage of ISOCAL Clear continuation; (iii) appetite evaluation; (iv) the percentage of targeted calorie achievement; (v) adverse events of NAC; (vi) postoperative complication rates; and (vii) postoperative hospital stay. Discussion: This prospective trial assesses the efficacy of nutritional support in addition to rehabilitation during NAC for patients with esophageal cancer. The results will be utilized in assessing whether the effects of nutritional support by ISOCAL Clear are promising or not and in planning future larger clinical trials.